Bacterial vaginosis in pregnancy: a current view on diagnosis and therapy (literature review)

Cover Page

Cite item

Full Text

Abstract

Bacterial vaginosis (BV) is the most prevalent lower genital tract disease in women of reproductive age (both pregnant and non-pregnant) and the most common cause of vaginal discharge and foul odor from the genital tract. To date, there is a lot of literature describing many different approaches to the diagnosis and treatment of BV during pregnancy. BV is common, and its precise prevalence varies widely depending on the patient population. Studies confirm that the prevalence of BV among pregnant women is the same as in the population of non-pregnant women, and ranges from 6 to 32%. The link between BV and a patient’s ethnicity, smoking, sexual behavior and douching was established. BV is more prevalent among African American women, smokers, sexually active women compared to virgins and those who use douching. Diagnosis of BV is based on clinical symptoms and the results of microbiological examination. Diagnostic criteria are the same for pregnant and non-pregnant women. If BV is confirmed, treat-ment is indicated. In most international guidelines on sexually transmitted infections, the use of either metronidazole 500 mg orally 2 times a day for 7 days, or clindamycin 300 mg orally 2 times a day for 7 days are recommended for the prevention of adverse obstetric outcomes. BV is considered as the risk factor for adverse obstetric outcomes, such as premature birth, premature rupture of membranes, spontaneous abortion, chorioamnionitis and postpartum infections, such as endometritis and infectious compli-cations in the area of the postoperative wound after cesarean section. Pregnant women with symptoms of BV are advised to be screened and treated to eliminate the symptoms. Treatment with oral or local antibiotics is acceptable to achieve recovery (cure) in pregnant women with a symptomatic course of BV and a low risk of adverse obstetric outcomes. Women without symptoms of BV and women without identified risk factors for preterm birth should not be routinely screened and treated for BV, while patients with an increased risk for premature birth may benefit from routine screening and treatment for BV.

About the authors

Tamara E Karapetyan

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: t_karapetyan@oparina4.ru
D. Sci. (Med.) Moscow, Russia

Natalya A Lomova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Cand. Sci. (Med.) Moscow, Russia

Valeria R Yusubova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Clinical Resident Moscow, Russia

Shota G Gvenetadze

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Clinical Resident Moscow, Russia

References

  1. Fleury F.J. Adult vaginitis. Clin Obstet Gynecol 1987; 24: 407e38
  2. Rein M.F, Holmes K.K. Non-specific vaginitis, vulvovaginal candidiasis, and trichomoniasis: clinical features, diagnosis and management. Curr Clin Top Infect Dis 1983; 4: 281e315.
  3. Gravett M.G, Hammel D, Eschenbach D.A et al. Preterm labor associa-ted with subclinical amniotic fluid infection and with bacterial vagino-sis. Obstet Gynecol 1986; 67: 229e37.
  4. Hillier S.L, Martius J, Krohn M.A et al. A case-control study of chorio-amnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319: 972e8.
  5. Hillier S.L, Nugent R.P, Eschenbach D.A et al.; for the Vaginal Infections and Prematurity Study Group. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 1995; 333: 1737e42.
  6. Korn A.P, Bolan G, Padian N et al. Plasma cell endometritis in women with symptomatic bacterial vaginosis. Obstet Gynecol 1995; 85: 387e90.
  7. Leitich H, Bodner-Adler B, Brunbauer M et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003; 189: 139e47.
  8. Minkoff H, Brunebaum A.N, Schwartz R.H et al. Risk factors for prema-turity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol 1984; 150: 965e72.
  9. Shennan A, Crawshaw S, Briley A et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cer-vicovaginal fetal fibronectin: the PREMET trial. BJOG 2006; 113: 65e74.
  10. Watts D.H, Krohn M.A, Hillier S.L et al. Bacterial vaginosis as a risk fac-tor for postcesarean endometritis. Obstet Gynecol 1990; 75: 52e8.
  11. Wiesenfeld H.C, Hillier S.L, Krohn M.A et al. Lower genital tract infec-tion and endometritis: Insight in to subclinical pelvic inflammatory di-sease. Obstet Gynecol 2002; 100: 456e63.
  12. Woolf S.H, Battista R.N, Angerson G.M et al.; Canadian Task Force on Preventive Health Care. New grades for recommendations from the Ca-nadian Task Force on Preventive Health Care. CMAJ 2003; 169: 207e8.
  13. Eschenbach D.A. Bacterial vaginosis: Emphasis on upper genital tract complications. Obstet Gynecol Clin North Am 1989;16:593e610
  14. Spiegel C.A, Amsel R, Eschenbach D et al. Anaerobic bacteria in non-specific vaginitis. N Engl J Med 1980; 303: 601e7.
  15. Hill G.B, Eschenbach D.A, Holmes K.K. Bacteriology of the vagina. Scand J Urol Nephrol Suppl 1985; 86: 23e39.
  16. Hillier S.L. Diagnostic microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993; 169: 455e9.
  17. Bump R.C, Zuspan F.P, Buesching W.J 3rd et al. The prevalence, six-month persistence, and predictive values of laboratory indicators of bacterial vaginosis (nonspecific vaginitis) in asymptomatic women. Am J Obstet Gynecol 1984; 150: 917e24.
  18. Hill L.H, Ruperalia H, Embil J.A. Nonspecific vaginitis and other genital infections in three clinic populations. Sex Transm Dis 1983; 10: 114e8.
  19. Amsel R, Totten P.A, Spiegel C.A et al. Nonspecific vaginitis: Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74: 14e22.
  20. Embrеe J, Caliando J.J, McCormack W.M. Nonspecific vaginitis among women attending a sexually transmitted diseases clinic. Sex Transm Dis 1984; 11: 81e4.
  21. Eschenbach D.A, Hillier S, Critchlow C et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988; 158: 819e28.
  22. Paavonen J, Heinonen P.K, Aine R et al. Prevalence of nonspecific vagi-nitis and other cervicovaginal infections during the third trimester of pregnancy. Sex Transm Dis 1986; 13: 5e8.
  23. Kurki T, Sivonen A, Renkonen O-V et al. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol 1992; 80: 173e7.
  24. Platz-Christensen J.J, Pernevi P, Hagmar B et al. A longitudinal follow-up of bacterial vaginosis during pregnancy. Acta Obstet Gynecol Scand 1993; 72: 99e102.
  25. Meis P.J, Goldenberg R.L, Mercer B et al. The preterm prediction study: significance of vaginal infections. Am J Obstet Gynecol 1995; 173: 1231e5.
  26. Wenman W.M, Tataryn I.V, Joffres M.R et al. Demographic, clinical and microbiological characteristics of maternity patients: a Canadian clini-cal cohort study. Can J Infect Dis 2002; 13: 311e8.
  27. Goldenberg R, Klebanoff M, Nugent R et al.; for the Vaginal Infections and Prematurity Study Group. Bacterial colonization of the vagina du-ring pregnancy in four ethnic groups. Am J Obstet Gynecol 1996; 174: 1618e21.
  28. Jonsson M, Karlsson R, Rylander E et al. The associations between risk behavior and reported history of sexually transmitted diseases, among young women: a population based study. Int J STD AIDS 1997; 8: 501e5.
  29. Bump R, Buesching W.B 3rd. Bacterial vaginosis in virginal and se-xually active adolescent females: evidence against exclusive sexual transmission. Am J Obstet Gynecol 1988; 158: 935e9.
  30. Hawes S.E, Hillier S.L, Benedetti J et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis 1996; 174: 1058e63.
  31. Klebanoff M.A, Hauth J.C, MacPherson C.A et al. Time course of the re-gression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. Am J Obstet Gynecol 2004; 190: 363e70.
  32. McDonald H, Brocklehurst P, Parsons J et al. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2007: CD000262.
  33. Sarwal S. Vaginal discharge (bacterial vaginosis, vulvovaginal candi-diasis, trichomoniasis). In: Canadian guidelines on sexually transmitted infections. 2006 edition. Ottawa: Public Health Agency of Canada, 2006; p. 106e21.
  34. Guise J.M, Mahon S.M, Aickin M et al. Screening for bacterial vaginosis in pregnancy. Am J Prev Med 2001; 20 (Suppl. 3): 62e72.
  35. Burtin P, Taddio A, Ariburnu O et al. Safety of metronidazole in pre-gnancy: a meta-analysis. Am J Obstet Gynecol 1995; 172: 525e9.
  36. Caro-Paton T, Carvajal A, Martin de Diego I et al. Is metronidazole teratogenic: a meta-analysis. Br J Clin Pharmacol 1997; 44: 179e82.
  37. Van Schalkwyk J, Money D.M. Pregnancy. In: Canadian guidelines on sexually transmitted infections. 2006 edition. Ottawa: Public Health Agency of Canada, 2006; p. 273e91.
  38. McGregor J.A, French J.I, Jones W et al. Bacterial vaginosis is associa-ted with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol 1994; 170: 1048e60.
  39. McGregor J.A, French J.I, Parker R et al. Prevention of premature birth by screening and treatment for common genital tract infections: Results of a prospective controlled evaluation. Am J Obstet Gynecol 1995; 173: 157e67.
  40. Hauth J.C, Goldenberg R.L, Andrews W.W et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995; 333: 1732e6.
  41. McDonald H.M, O’Loughlin J.A, Vigneswaran R et al. Bacterial vagino-sis in pregnancy and efficacy of short-course oral metronidazole trea-tment: a randomized controlled trial. Obstet Gynecol 1994; 84: 343e8.
  42. Carey J.C, Klebanoff M.A, Hauth J.C et al. Metronidazole to prevent pre-term delivery in pregnant women with asymptomatic bacterial vagino-sis. N Engl J Med 2000; 342: 534e40.
  43. Ugwumadu A, Reid F, Hay P et al. Natural history of bacterial vagino-sis and intermediate flora in pregnancy and effect of oral clindamycin. Obstet Gynecol 2004; 104: 114e9.
  44. Joesef M.R, Hillier S.L, Wiknjosastro G et al. Intravaginal clindamycin treatment for bacterial vaginosis: Effects on preterm delivery and low birth weight. Am J Obstet Gynecol 1995; 173: 1527e31.
  45. Kekki M, Kurki T, Pelkonen J et al. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet Gynecol 2001; 97: 643e8.
  46. Kurkinen-Räty M, Vuopala S, Koskela M et al. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. BJOG 2000; 107: 1427e32.
  47. Lamont R.F, Jones B.M, Mandal D et al. The efficacy of vaginal clinda-mycin for the treatment of abnormal genital tract flora in pregnancy. In-fect Dis Obstet Gynecol 2003; 11: 181e9.
  48. Yudin M.H, Landers D.V, Meyn L et al. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol 2003; 102: 527e34.
  49. Guaschino S, Ricci E, Franchi M et al. Treatment of asymptomatic bac-terial vaginosis to prevent preterm delivery: a randomized trial. Eur J Obstet Gynecol Reprod Biol 2003; 110: 149e52.
  50. Morales W.J, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebocontrolled, double-blind study. Am J Obstet Gynecol 1994; 171: 345e7.
  51. Okun N, Gronau K.A, Hannah M.E. Antibiotics for bacterial vaginosis or trichomonas vaginalis in pregnancy: a systematic review. Obstet Gyne-col 2005; 105: 857e68.
  52. Vermeulen G, Bruinse H. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: A randomized placebo controlled double blind trial. Br J Obstet Gynaecol 1999; 106: 652e7.
  53. Lamont R.F, Duncan S.L.B, Mandal D et al. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003; 101: 516e22.
  54. Leitich H, Brunbauer M, Bodner-Adler B et al. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol 2003; 188: 752e8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».